It has been reported that the synergy of PI3K and CDK4/6 inhibitors increases apoptosis and cell cycle arrest in triple-negative breast cancer cells, and that tumor immunogenicity is enhanced [72]. The gene discussed is CDK4; the disease is triple-negative breast carcinoma.